Subtle differences in iPS cells spur research

07/19/2010 | Boston Globe (tiered subscription model), The

Scientists in the U.S. and abroad are examining the characteristics and usefulness of induced pluripotent stem cells, adult cells that are reprogrammed to become embryoniclike stem cells, after discovering slight differences that could affect the potential of iPS cells in treating diseases. "We are getting a variety of signals that suggest they are different [from embryonic stem cells] in key ways, and the road to using them as a therapy will require much more refinement of this big tool," said Konrad Hochedlinger, a chief faculty member at the Harvard Stem Cell Institute.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD